Peptide Stacks and Protocols: How to Combine Peptides Effectively

Key Takeaways

• Regulatory Status: As of April 2026, no multi-compound injectable peptide regimen combining investigational compounds is FDA-approved. Tirzepatide (Mounjaro, Zepbound) is an FDA-approved single molecule with dual GIP/GLP-1 receptor agonist activity — it is not a combination of two peptides. Each compound in any investigational multi-compound plan must be individually assessed for regulatory status.
• Research Stage: GHRH analog plus ghrelin receptor agonist combinations have human pharmacokinetic evidence showing a larger acute GH release with co-administration than with either compound alone. BPC-157 and thymosin beta-4 (TB-500) have primarily preclinical data. Metabolic peptide combinations are clinical territory requiring individual risk-benefit assessment. Note: on April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including CJC-1295 and ipamorelin on the 503A bulk drug substances list.
• Availability: Injectable peptide combination therapy requires individual prescriptions for each compound through 503A compounding pharmacies. Each compound's compounding eligibility must be separately verified.
• How it works: Where combination therapy has a pharmacological basis, it involves compounds targeting complementary or synergistic receptor pathways. For most investigational peptide combinations, no controlled clinical trial data supports the combination as a combination; the rationale should be mechanistic evidence, not shared wellness-market categorization.
• What the evidence shows: Synergistic GH release with GHRH plus GHRP combinations is pharmacokinetically documented in humans. Tissue repair combination data is substantially preclinical. No clinical trial has studied most common wellness-market peptide combinations as combinations.

The concept of combining multiple peptides in a supervised therapy plan has a legitimate pharmacological foundation in some cases and none in others. The distinction is mechanism. When two compounds activate different receptor pathways converging on the same biological endpoint, combining them can produce greater or more sustained effects than either compound alone — and this has been documented in human pharmacokinetic studies for GH secretagogue combinations. When compounds are combined based on shared marketing category ("healing peptides," "performance peptides") without mechanistic rationale or clinical data, the combination is speculative. The clinical evaluation of any multi-compound therapy plan begins with understanding each compound independently.

The Pharmacological Basis for Combination Peptide Therapy

When combinations are mechanistically rational

Synergistic receptor pharmacology provides the strongest foundation for combining peptide compounds. The most documented example in the GH secretagogue category involves GHRH (growth hormone-releasing hormone) analogs and ghrelin receptor agonists. GHRH binds the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and release. Ghrelin receptor agonists (GHRPs, including ipamorelin) bind the growth hormone secretagogue receptor (GHSR) on the same cells through a distinct molecular pathway. Argente and colleagues published a 1996 clinical review in Hormone Research establishing that GHRPs stimulate GH release via a receptor distinct from the GHRH receptor — providing the mechanistic basis for why combining the two receptor pathways produces a greater acute GH release in published pharmacokinetic studies than either compound alone. This is the pharmacological basis cited for combining GHRH analogs with ghrelin receptor agonists — two compounds acting on two distinct receptors in the same cell population.

When combinations lack mechanistic basis

Many combinations circulating in the wellness market pair compounds from shared marketing categories (recovery peptides, anti-aging peptides, performance peptides) without pharmacological synergy rationale. Where compounds target unrelated pathways or operate through mechanisms that have not been studied for interaction, the combination is speculative at best. The safety concern is not just efficacy uncertainty — it is the absence of any interaction data in humans for most investigational peptide combinations. A 2013 review by Ferrari published in Arquivos Brasileiros de Endocrinologia e Metabologia documented serious health complications from peptide hormone misuse in sport, including glucose dysregulation, muscle damage, and cancer risk signals, arising specifically from unmonitored use of GH-related peptides outside clinical supervision. The risks are not theoretical.

GHRH Analogs and Ghrelin Receptor Agonists

CJC-1295: sustained GHRH analog activity

CJC-1295 is a synthetic GHRH analog modified with a molecular complex that binds to serum albumin, extending its half-life from minutes to several days. A human pharmacokinetic and pharmacodynamic trial by Teichman and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2006 demonstrated that single subcutaneous doses of CJC-1295 in healthy adults produced 2 to 10-fold increases in mean plasma GH concentration lasting more than 6 days, with sustained IGF-1 elevation. These human pharmacokinetic data are foundational to the mechanistic rationale for CJC-1295. CJC-1295 is not FDA-approved and has historically been accessed through 503A compounding with a licensed provider prescription. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including CJC-1295 on the 503A bulk drug substances list; compounding access may be restricted pending FDA action on this recommendation. Evidence stage: human pharmacokinetic/pharmacodynamic data; regulatory status: not FDA-approved, subject to April 22, 2026 adverse PCAC recommendation.

Ipamorelin: the selective ghrelin receptor agonist

Ipamorelin is a pentapeptide ghrelin receptor agonist designed to stimulate GH release without the cortisol and ACTH elevation associated with earlier GHRPs. Raun and colleagues published a landmark characterization in the European Journal of Endocrinology in 1998 describing ipamorelin as the first highly selective GH secretagogue — one that stimulates GH release at a magnitude comparable to GHRH-mediated release without meaningfully elevating cortisol or ACTH. This selectivity profile is the pharmacological reason ipamorelin has been discussed alongside older GHRPs in research contexts. Ipamorelin's short half-life (approximately 2 hours) means it produces a pulsatile GH response rather than sustained elevation. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including ipamorelin on the 503A bulk drug substances list; compounding access may be restricted pending FDA action. Evidence stage: animal plus early human data; regulatory status: not FDA-approved, subject to April 22, 2026 adverse PCAC recommendation.

Sermorelin: the shorter-acting GHRH analog

Sermorelin acetate (GHRH 1-29 amide) was previously FDA-approved under two separate NDAs: Geref (pediatric GH deficiency therapy, approved 1997) and Geref Diagnostic (adult GH diagnostic testing, approved 2004). Both formulations were commercially discontinued by the sponsor, and no sermorelin product currently holds active FDA approval. A review by Prakash and Goa published in BioDrugs in 1999 characterized sermorelin's mechanism and clinical evidence base in the context of GH deficiency treatment. The sermorelin product previously held FDA approval but has since been discontinued; no currently-marketed sermorelin product holds FDA approval. CJC-1295 has never held FDA approval. Sermorelin is available in the U.S. only through 503A compounding pharmacies with a valid prescription, and its eligibility for 503A compounding is unchanged as of April 2026. Its shorter half-life (10–20 minutes) more closely mimics the natural pulsatile pattern of endogenous GHRH release, making it physiologically distinct from the sustained CJC-1295 profile. Evidence stage: human clinical evidence; regulatory status: not currently FDA-approved as a compounded formulation; available through 503A compounding with a prescription.

Tesamorelin: the FDA-approved GHRH analog

Tesamorelin is the only GHRH analog with current FDA approval, indicated specifically for HIV-associated lipodystrophy. Its evidence base is the most robust in the GH secretagogue class. A pivotal trial by Falutz and colleagues published in 2007 in the New England Journal of Medicine enrolled 412 HIV-positive patients and demonstrated 15.2% reduction in visceral adipose tissue versus 5.0% increase with placebo over 26 weeks. A follow-up metabolic analysis by Stanley and colleagues published in Clinical Infectious Diseases in 2012 showed that tesamorelin responders had significantly improved triglycerides, adiponectin, and glucose homeostasis. Tesamorelin is classified as a biologic under the BPCIA (2020) and cannot be lawfully produced through 503A compounding — only the FDA-approved product (Egrifta) is legally available. Use outside the HIV-lipodystrophy indication is off-label. A clinical overview by Spooner and Olin in Annals of Pharmacotherapy in 2012 reviewed tesamorelin's clinical profile including its visceral fat reduction over 26 to 52 weeks in the approved indication. Compounded preparations marketed as "tesamorelin" from non-FDA-approved sources are not a legitimate regulatory pathway and do not meet the Biologics Price Competition and Innovation Act requirements for biologic products. Evidence stage: human randomized controlled trial; regulatory status: FDA-approved for HIV-associated lipodystrophy only; tesamorelin is a biologic and cannot be compounded.

MK-677: the oral ghrelin mimetic

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that stimulates GH and IGF-1 secretion without peptide structure. A 2-year randomized trial by Nass and colleagues published in the Annals of Internal Medicine in 2008 showed sustained elevation of GH and IGF-1 to young-adult levels plus 1.1 kg increase in fat-free mass in healthy older adults. MK-677 is not FDA-approved for any indication. It has not been approved for inclusion on the 503A bulk drug substances list and is not legally available through licensed compounding pharmacies in the United States. MK-677 is also listed on the WADA Prohibited List. Evidence stage: human randomized controlled trial; regulatory status: not FDA-approved, not available through licensed compounding.

BPC-157 and TB-500: Investigational Compounds with Restricted Compounding Access

BPC-157: preclinical evidence and regulatory status

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice protein. Its proposed mechanism in tissue repair centers on fibroblast biology: a 2011 mechanistic study by Chang and colleagues in the Journal of Applied Physiology showed that BPC-157 accelerates tendon healing in rats via enhanced tendon-fibroblast outgrowth, survival, and migration through FAK-paxillin pathway activation. The GI evidence was characterized in reviews by Sikiric and colleagues in Current Pharmaceutical Design in 2011 and in Current Medicinal Chemistry in 2012. However, a 2025 systematic review by Vasireddi and colleagues in the HSS Journal reviewed 36 BPC-157 studies and found only one small retrospective clinical study among them — the remainder are preclinical. Human safety data remain limited to a pilot IV study by Lee and colleagues in 2025 showing no measurable biomarker effects in two healthy adults. As of April 2026, BPC-157 is classified as an FDA Category 2 bulk drug substance; its 503A compounding has been restricted since the February 2026 reclassification and remains restricted as of April 2026. It is not available through most licensed compounding pharmacies. Evidence stage: animal-model preclinical, no completed human randomized controlled trial; regulatory status: Category 2 compounding restriction.

Thymosin beta-4 (TB-500): tissue repair via a different mechanism

TB-500 is a synthetic peptide derived from the C-terminal region of thymosin beta-4, an endogenous actin-sequestering protein. Its proposed mechanism in tissue repair is distinct from BPC-157: thymosin beta-4 facilitates tissue repair by promoting cell migration, reducing apoptosis, decreasing inflammatory scarring, and influencing wound angiogenesis. Goldstein and colleagues published a comprehensive review of thymosin beta-4's tissue repair role in Expert Opinion on Biological Therapy in 2012 characterizing these mechanisms. Treadwell and colleagues, writing in the Annals of the New York Academy of Sciences in 2012, reported thymosin beta-4 acceleration of dermal healing in animal models and in human chronic skin ulcer trials. The human wound trial data are the strongest clinical evidence for thymosin beta-4 — but they are wound healing trials, not athletic injury or musculoskeletal repair trials. TB-500 is not FDA-approved and has no established eligibility for 503A compounding as of April 2026. Evidence stage: limited human data from wound closure trials; no completed human randomized controlled trial for musculoskeletal repair indications; regulatory status: not FDA-approved, no established 503A eligibility.

What BPC-157 and TB-500 are not

Neither BPC-157 nor TB-500 has completed Phase 3 human clinical trials for any indication. Neither is FDA-approved. The combination of the two compounds, widely discussed in wellness contexts, has no dedicated clinical trial basis — it is a theoretically complementary combination of two preclinical compounds whose individual evidence is itself incomplete. Any provider prescribing either compound should frame it explicitly as investigational use and should have a monitoring plan in place. AOD-9604, sometimes added to tissue-repair combinations for purported fat-loss effects, is discussed further in the AOD-9604 section of this article's metabolic combinations H2 below; it is an investigational compound with a failed Phase 2b obesity trial and is subject to FDA Category 2 compounding restrictions. Evidence stage: animal-model data only for the combination; regulatory status: both compounds subject to Category 2 restriction on compounding.

Metabolic Combinations and GLP-1 Therapy

Single-molecule dual agonists: the FDA-approved approach

The most evidence-supported "combination" in metabolic peptide therapy is tirzepatide, a single molecule that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. A review by Syed published in Drugs in 2022 characterized tirzepatide as a dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for type 2 diabetes. This is not a multi-compound combination — it is a single engineered molecule. The clinical outcomes from tirzepatide's trial program exceed those seen with single GLP-1 receptor agonists, consistent with additive receptor agonism from the GIP pathway. Evidence stage: human randomized controlled trial; regulatory status: FDA-approved.

AOD-9604 and metabolic combinations

AOD-9604 is a synthetic fragment of the growth hormone C-terminus proposed to have lipolytic activity independent of the standard hGH receptor. A 2001 study by Heffernan and colleagues in the International Journal of Obesity and Related Metabolic Disorders demonstrated fat oxidation in obese mice via beta-3 adrenergic pathway activity. Preclinical fat-oxidation findings in obese mice have not been replicated in peer-reviewed human efficacy trials for weight loss. AOD-9604 is an FDA Category 2 compound as of April 2026 — compounding is restricted. It is not an appropriate addition to metabolic combination therapy. Evidence stage: failed human randomized controlled trial; regulatory status: Category 2 compounding restriction.

What to Test Before Multi-Compound Peptide Therapy

Any multi-compound therapy plan expands the surface area for adverse effects and biomarker changes. Baseline testing should comprehensively cover all pathways the planned compounds affect.

• IGF-1: Essential for any GH secretagogue or GHRH analog combination. IGF-1 reflects integrated pituitary GH output and is the primary monitoring marker for GH secretagogue response and adverse signal detection.
• Fasting glucose and HbA1c: GH secretagogues can impair insulin sensitivity. Baseline fasting glucose and HbA1c characterize the pre-treatment metabolic state against which any insulin resistance signal during therapy can be interpreted.
• Triglycerides and lipid panel: GH axis activation influences lipid metabolism. Baseline triglycerides are among the most responsive markers for GHRH analog therapy (tesamorelin showed meaningful triglyceride improvements in HIV-lipodystrophy trials).
• hs-CRP: For tissue repair combinations, a baseline hs-CRP characterizes systemic inflammatory status. If a compound produces anti-inflammatory effects, this baseline makes that change detectable.
• eGFR: Renal function affects elimination of injectable compounds. A baseline eGFR is part of standard pre-treatment assessment for multi-compound injectable regimens.
• Complete metabolic panel (ALT, AST, electrolytes): Hepatic function and electrolyte baseline are standard safety assessments before initiating any prescription peptide regimen involving multiple compounds.
• Insulin: Fasting insulin characterizes insulin resistance independent of glucose levels. Especially relevant before GH secretagogue therapy where insulin resistance is a known monitored risk.

The more compounds in a therapy plan, the more important a comprehensive baseline becomes. A change in any biomarker during multi-compound therapy is difficult to attribute to a specific compound without a pre-treatment reference. The metabolic health biomarker testing guide provides clinical context for each of these markers.

What Your Labs May Show During Multi-Compound Therapy

For GH secretagogue combinations, providers typically monitor IGF-1 (expected increase into the reference range with GH stimulation), fasting glucose (monitored for insulin resistance signal), and body composition changes. Triglycerides may improve with tesamorelin-class therapy or in metabolic responders. For tissue repair compounds (BPC-157, TB-500), no validated biomarker response profile exists in humans — which is itself a reflection of the limited human trial data. For any combination involving a metabolic compound, HbA1c and fasting glucose are tracked throughout the therapy duration.

The principle behind comprehensive monitoring — objective data before any clinical decision, and ongoing data to interpret response — is a standard expectation in any prescription therapy. In the context of multi-compound therapy specifically, comprehensive baseline and follow-up testing is how a provider and patient can interpret biomarker changes against a pre-treatment reference. Superpower's preventive health testing platform supports the baseline measurement of the markers discussed above; prescribing, dosing, and monitoring decisions for any specific peptide regimen are made by licensed providers.

Regulatory Status and How to Access Multi-Compound Therapy

FDA approval status

As of April 2026, no multi-compound injectable peptide regimen combining investigational compounds (CJC-1295, ipamorelin, BPC-157, TB-500, etc.) has FDA approval. Each compound must be individually evaluated for approval status. Tesamorelin is FDA-approved for HIV-associated lipodystrophy and cannot be compounded (biologic classification). Sermorelin is available through 503A compounding with a valid prescription, and its eligibility for 503A compounding is unchanged as of April 2026. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including CJC-1295 and ipamorelin on the 503A bulk drug substances list; compounding access for these compounds may be restricted pending FDA action. BPC-157 is Category 2 with restricted compounding. TB-500 is not FDA-approved and has no established 503A eligibility. Compounds on the Category 2 list cannot legally be combined into a compounded multi-compound injection under current 503A rules.

Compounding access and 503A/503B

As of April 2026, 503A pharmacies can compound individual peptides that appear on the 503A bulk drug substance Category 1 list with valid prescriptions. Compounding combinations requires that each component individually qualify for compounding. The February 2026 reclassification actions restricted several commonly discussed peptides (BPC-157) to Category 2 status, which limits their inclusion in any compounded formulation. Providers and patients relying on multi-compound compounded formulations should verify the current regulatory status of each component with their prescribing physician and compounding pharmacy before initiating or continuing any such regimen.

Cost and insurance framing

Injectable peptide combination therapy through 503A compounding pharmacies is typically not covered by insurance — compounded formulations of non-approved compounds are outside standard formulary coverage. FDA-approved peptides prescribed for their approved indications may qualify for coverage with prior authorization. HSA and FSA accounts may cover prescribed peptide therapy regimens. The evaluation process through a licensed provider includes clinical consultation, relevant baseline lab work, and ongoing monitoring — costs vary by provider and compound.

How to Evaluate a Provider for Multi-Compound Therapy

A clinically rigorous provider for multi-compound peptide therapy will evaluate each compound independently before combining, require comprehensive baseline laboratory assessment, and maintain monitoring throughout. Providers who present multi-compound injectable regimens as standardized protocols without individualized baseline assessment represent the lower end of the clinical quality spectrum in this space. The questions below reveal how rigorously a provider approaches this category.

Questions to ask before starting with any provider:

• What is the evidence basis for each compound in this regimen, and what is each compound's current regulatory status?
• Which compounds in this regimen are on the FDA's Category 2 bulk drug substances list, and how does that affect compounding eligibility?
• Were any of these compounds the subject of an adverse recommendation by the FDA's Pharmacy Compounding Advisory Committee (PCAC) in 2026, and how does that affect access going forward?
• What baseline laboratory assessment do you require before initiating a multi-compound regimen?
• How frequently will you recheck labs during the regimen, and which specific markers will you track?
• What is the safety monitoring plan if I experience unexpected symptoms?
• Which 503A-accredited pharmacy sources the compounded compounds in this regimen?

Any evaluation of GH secretagogue therapy, including single-compound starting points, begins with provider consultation and baseline laboratory assessment through a licensed healthcare provider.

Important Safety Information

This article discusses multi-compound peptide therapy as a category, including both FDA-approved medications and compounds not FDA-approved for human use. The terminology "peptide stacks" is a wellness-market term, not a clinical or regulatory term. This article uses "combination therapy" and "multi-compound therapy plan" to reflect accurate clinical framing.

As of April 2026, no multi-compound injectable peptide regimen combining investigational compounds (CJC-1295, ipamorelin, BPC-157, TB-500, etc.) is FDA-approved. BPC-157 is classified as an FDA Category 2 bulk drug substance; its 503A compounding was restricted by the February 2026 reclassification and remains restricted as of April 2026. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including CJC-1295 and ipamorelin on the 503A bulk drug substances list. TB-500 is not FDA-approved and has no established 503A eligibility. Tesamorelin is a biologic that cannot be lawfully compounded under 503A — only the FDA-approved product, Egrifta, is legally available; compounded preparations marketed as "tesamorelin" from non-FDA-approved sources are not a legitimate regulatory pathway.

Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Bremelanotide (Vyleesi, PT-141) is FDA-approved only for hypoactive sexual desire disorder (HSDD) in premenopausal women. Tirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes and chronic weight management. Use of any of these compounds for other indications is not FDA-approved and reflects the independent clinical judgment of the prescribing physician.

Superpower is a technology platform that connects members with licensed healthcare providers and testing services. Medications are prescribed and dispensed by licensed providers and licensed pharmacies; Superpower itself does not prescribe or dispense medications, and does not offer unmonitored multi-compound injection protocols.

This content is not a substitute for medical advice, diagnosis, or treatment. The risks of unmonitored peptide use include glucose dysregulation, immunogenic reactions, and sourcing-related contamination. Always consult a qualified healthcare provider before initiating any peptide therapy, particularly multi-compound regimens.